Dendreon Corporation Added to Russell 3000 and Russell 2000 Stock Indexes.Business Editors/Health/Medical Writers BIOWIRE2K SEATTLE--(BUSINESS WIRE)--July 1, 2003 Dendreon Corporation (Nasdaq:DNDN) today announced that the Company has been added to the Russell 3000(R) and Russell 2000(R) stock indexes, widely used as benchmarks for investment strategies. The Russell 3000(R) Index is composed of the 3,000 largest companies in the U.S. stock market by market capitalization Market Capitalization A measure of a public company's size. Market capitalization is the total dollar value of all outstanding shares. It's calculated by multiplying the number of shares times the current market price. This term is often referred to as market cap. as of the end of May. Companies who are members of the Russell 3000 (R)Index are automatically included in either the large-cap Russell 1000(R) Index or the small-cap Russell 2000(R) Index. Dendreon has been added to the widely used Russell 2000(R) Index. Dendreon was added to the indexes as part of Frank Russell Company's annual reconstitution of U.S. equity indexes. The index membership, which went into effect today, will remain effective for one year. Inclusion in the Russell indexes Russell Indexes US equity index widely used by pension and mutual fund investors that are weighted by market capitalization and published by the Frank Russell Company of Tacoma, Washington. is determined by total market capitalization Total Market Capitalization The total market value of all of a firm's outstanding securities. and style attributes, rather than by subjective opinion or committee decisions. Frank Russell Company produces 21 U.S. equity indexes, which are all subsets of the Russell 3000 Index The Russell 3000 Index is a stock market index of US stocks. The ticker is "RUA" or similar. See Russell Indexes page for main discussion. See also the iShares Russell 3000. . Approximately $250 billion is invested in funds that use Russell's indexes. Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. The Company's lead investigational product candidate, Provenge(R), is a cancer immunotherapy undergoing a pivotal Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. for the potential treatment of androgen independent prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . In addition to its immunotherapies in clinical and preclinical development for a variety of cancers, Dendreon's product pipeline also includes monoclonal antibody and small molecule product candidates. Dendreon has established important research and development alliances with industry leaders Genentech, Inc. and Kirin Brewery Co., Ltd. For more information about the Company and its programs, visit www.dendreon.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion